

# Beyond DNA Removal: Assessing the Immunological Response to Decellularized Rabbit Dermal Matrices

Marta Rosadas<sup>1</sup>, Christian Sánchez Espinel<sup>2,3</sup>, Mercedes Peleteiro<sup>2,3</sup>, Alda Sousa<sup>4</sup>, Viviana P. Ribeiro<sup>\*1</sup>, África González-Fernández<sup>2,3</sup>, Ana L. Oliveira<sup>1</sup>

1 - CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Porto, Portugal

2 - CINBIO, Immunology Group, Universidade de Vigo, 36310, Vigo, Spain

3 - Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO

4 - Cortadoria Nacional de Pêlo, S.A., S. João da Madeira, Portugal.

\* vpribeiro@ucp.pt



CATOLICA  
FACULTY  
OF BIOTECHNOLOGY

PORTO

CORTADORIA




iberos  
Instituto de Biofabricación en Red  
para el Envejecimiento Saludable

## INTRODUCTION


Decellularized matrices have attracted considerable attention in tissue engineering and regenerative medicine due to their ability to preserve the biochemical composition and microarchitecture of native tissues [1]. Although DNA removal is commonly used as the main indicator of decellularization efficiency, other factors—such as endotoxin contamination, damage-associated molecular patterns, and residual reagents—can significantly influence the host immune response [2,3].

In this study, decellularized rabbit dermal matrices (dRDM) produced using two different protocols—resulting in DNA levels below or above the proposed safety threshold of 50 ng/mg dry tissue—were evaluated for their immunological performance.



## MATERIALS AND METHODS

### DECELLULARIZATION PROTOCOL



For all the assays were used 8mm punched samples.

### ENDOTOXIN QUANTIFICATION


≈ 100mg of sample were incubated in 40mL of endotoxin free water at 37°C for 24 hours. Endotoxin concentration of the leachable was quantified using LAL Assay.

### STERILITY VERIFICATION

- ✓ Turbidity test
- ✓ Agar LB incubation test

Peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood samples from healthy donors before each assay through Ficoll density gradient centrifugation.

Samples of dRDM of both protocols were analyzed in 3 forms:



### ROS PRODUCTION INDUCTION

4H INCUBATION  
• dRDM samples  
• Positive control: PMA  
• Negative control: just cells

H<sub>2</sub>DCFDA (DCFH-DA) ROS assay → Flow cytometry

### ANNEXIN V ASSAY

OVERNIGHT INCUBATION  
• dRDM samples  
• Positive control: PMA  
• Negative control: just cells

Annexin V Assay → Flow cytometry



### COMPLEMENT ACTIVATION

1H INCUBATION  
• dRDM samples  
• Positive control: Zymosan A  
• Negative control: just plasma


Western Blot for C3, C3a and C3b identification

Significant activation was considered when the band had ≥2 times the % relative intensity of the negative control.

## RESULTS AND DISCUSSION



All conditions showed ROS levels comparable to the negative control, while the positive control induced a marked increase in ROS. These results indicate that dRDMs and their released products induce minimal immune activation and oxidative stress.





dRDMs were successfully obtained using both protocols, which significantly reduced DNA content. The SDC 3H protocol met the recommended threshold (<50 ng DNA/mg dry tissue), while the SDC 30 min protocol also achieved low residual DNA levels (xxxx). Endotoxin levels in both dRDMs were below the FDA limit (0.5 EU/mL) for this type of medical device.

### Proteomic analysis

Protein Name	Gene Symbol	SDC 30MIN	SDC 3H
Collagen type I alpha 1 chain	COL1A1	High	Low
Collagen type I alpha 2 chain	COL1A2	High	Low
Collagen type III alpha 1 chain	COL3A1	Low	High
Collagen type V alpha 2 chain	COL5A2	Low	High

Proteomic analysis revealed that both dRDMs were predominantly collagenous. The SDC 30 min protocol preserved a collagen profile similar to native dermis, while the SDC 3H showed alterations suggestive of collagen degradation, potentially associated with damage-associated molecular patterns (DAMPs) release and compromised tissue integrity.


### Complement Activation



Dry matrices from both protocols induced complement activation, likely due to exposure of collagen-associated triggering moieties while dehydrated. Among hydrated matrices, only the SDC 3H dRDM showed significant activation, although at lower levels than the positive control.

Annexin V assays showed comparable levels of healthy cells across all samples and the negative control. Hydrated dRDMs produced with the SDC 30 min protocol showed the highest viability and lowest apoptosis/necrosis, while dry matrices and hydrated SDC 3H dRDMs exhibited increased membrane damage (AN-/IP+). Leachables had only minor effects, indicating minimal detergent contribution.

Overall, the results suggest that cell responses were mainly driven by physical stress at the cell-matrix interface, exacerbated by collagen degradation and matrix dryness.



## CONCLUSIONS

Two decellularization protocols produced dRDMs with distinct biological profiles. Although the SDC 3H protocol achieved DNA levels below the recommended threshold, it was associated with greater collagen degradation, whereas the SDC 30 min protocol better preserved native dermal collagen. Both matrices were sterile, endotoxin-free, and did not induce ROS production in PBMCs. However, dry dRDMs and SDC 3H-treated matrices promoted complement activation and increased PBMC necrosis. Overall, despite not meeting the recommended DNA threshold, the SDC 30 min protocol demonstrated superior immunocompatibility and collagen preservation, highlighting that DNA content alone is not a reliable predictor of decellularization efficiency. Instead, immunocompatibility, collagen integrity, physical cell-matrix interactions, and potential detergent residues play a critical role in defining matrix performance.

## REFERENCES

- Rosadas M et al., 2024, *Frontiers in Biomaterials and Bio-Inspired Materials*
- Kasravi M et al., 2023, *Biomaterials Research*
- Cheng W et al., 2025, *Acta Biomaterialia*.

## ACKNOWLEDGEMENTS

This work was supported by IBEROS+ (0072\_IBEROS\_MAIS\_1\_E), INTERREG V- A España-Portugal (POCTEP 2021-2027) and Consolidación e estruturación de unidades de investigación competitivas, Xunta de Galicia (ED431B 2024/31). MR acknowledges the supported given by the Erasmus+ Program of the European Union through a mobility grant and private funding from Cortadoria Nacional de Pêlo, S.A. SKINNOVATE. VPR acknowledges FCT for her junior researcher contract 2023.07374.CEECIND and projects STAR-SKIN (2023.11204.PEX) and ALICE (2024.05237.RESTART).